Skip to main content

The Blavatnik Fund for Innovation at Yale

The Blavatnik Fund for Innovation at Yale

Accelerating the translation of early-stage life science research into impactful products. 

Since 2017, Yale has 63 projects with more than $20 million* in direct funding through the Blavatnik Fund for Innovation.

The Blavatnik Fund for Innovation at Yale is a $65 million fund that develops and translates Yale's ground breaking research into innovative healthcare solutions. The Fund is made possible by a generous grant from the Blavatnik Family Foundation in support of the commercialization of Yale faculty applied research and technology in the life sciences. The Fund’s integrated approach combines business expertise, intensive guidance, and essential funding to support innovative, Yale investigator-initiated research at all levels. The goal of completed projects are partnerships with industry, through licenses to existing biopharmaceutical companies,  startups, major industry-sponsored research agreements or external non-dilutive funding.  

Blavatnik By The Numbers


Funded Projects


Biotech Ventures Launched


Total Awards & Fellowships


Raised by Ventures


CRO Contracts

FDA Investigational New Drug (IND) Status

Clinical Trials Initiated

blavatnik applications

Applications are now closed for development and pilot awards.

Accelerator applications (mid-cycle) deadline: May 1, 2024.